JHS Svendgaard Laboratories: Board of Directors approved the unaudited standalone and consolidated financials for quarter and half year…
JHS Svendgaard Laboratories (JHS) filed a disclosure titled "Board of Directors approved the unaudited standalone and consolidated financials for quarter and half year ended 30 September, 2026". The company is valued at about ₹72.46 crore.
What happened
JHS Svendgaard Laboratories (JHS) filed a disclosure with the exchanges on 2 November 2026 at 06:26 PM titled "Board of Directors approved the unaudited standalone and consolidated financials for quarter and half year ended 30 September, 2026".
Company snapshot
JHS Svendgaard Laboratories is a micro-cap company, with a market value of about ₹72.46 crore.
The stock last traded at ₹8.29, against a 52-week range of ₹6.26–₹13.69 (39.4% below the high).
Before this filing the shares had moved −23.0% over the month and +5.5% over three months. Average daily turnover over the last 20 sessions was about ₹0.4 crore.
Promoters held 33.85% at the end of Q1 FY27. Foreign institutions owned 3.14% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 23 | 1.1 | 0.12 |
| Q2 FY26 | 46 | 0.9 | 0.1 |
| Q3 FY26 | 23 | 0.8 | 0.09 |
| Q4 FY26 | 33 | -3.6 | -0.42 |
| Q1 FY27 | 30 | 1.1 | 0.12 |
What history shows
BCEIE has no earlier approval filing from this company on record since May 2026.
Market-wide, 1,547 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- 2 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.